Canine Primary Hyperparathyroidism: Diagnosis and Treatment

Bottom line

Confirm a PTH-dependent ionized hypercalcemia pattern, localize abnormal tissue for a suitable intervention, and arrange postprocedure calcium surveillance before treatment. A reference-interval PTH may be inappropriate when calcium is high. [1] Separate confirmation of the endocrine disorder from the choice of procedure and the plan for its complications.

Confirm the mechanism before localizing the gland

The clinical review bases diagnosis on ionized hypercalcemia, inappropriately nonsuppressed PTH and exclusion of other causes. Cervical ultrasonography follows the clinicopathologic diagnosis and has operator-dependent limitations. [1]

Record concurrent calcium and PTH results, the performing laboratory, sample requirements, renal findings, phosphate and relevant exposures. Reconcile any calcium-modifying treatment already given with the interpretation of subsequent samples. Do not allow a visible neck lesion to end an unresolved hypercalcemia investigation.

For a credible vitamin D exposure, the cholecalciferol toxicosis reference addresses exposure-specific assessment. Its poisoning pathway should not be transplanted into a primary hyperparathyroidism treatment plan. Conversely, a parathyroid hypothesis should not erase a documented exposure.

Match the procedure to the lesion and available expertise

Surgery, ultrasound-guided ethanol ablation and heat ablation are described treatments. Ablation requires a lesion that can be reliably visualized and targeted; procedural expertise and anatomic relationships matter. [1]

Discuss localization confidence, suspected multiplicity, anesthesia, the need for tissue assessment, operator experience and follow-up capacity with the treating service. Explain what would count as initial treatment failure, persistent disease or recurrence. The choice should incorporate the patient's situation rather than a success percentage taken from a different center.

A prospective single-center study evaluated sonographic-appearance-guided ethanol ablation in selected dogs with persistent ionized hypercalcemia, nonsuppressed PTH and an identifiable presumed functional nodule, after excluding alternative causes. Of 49 enrolled dogs, 47 had follow-up; hypercalcemia resolved in 42. Minor and major complications were reported. [2]

That observational design provides an option-specific outcome estimate, not randomized evidence of equivalence to surgery. The study's treatment selection and specialist setting limit extrapolation to an unlocalized lesion or a different procedural environment. Do not convert its injected-volume association into a bedside dosing formula.

Plan for falling calcium before the intervention

Travail and colleagues retrospectively studied 103 dogs undergoing successful partial parathyroidectomy with a single identified nodule. Higher preoperative PTH was associated with postoperative hypocalcemia, but only 81 dogs entered the predictive analysis. Assays and reference intervals varied, and calcium assessment covered the first 72 postoperative hours. [3]

Use that evidence to inform discussion of risk rather than supply a universal discharge cutoff. The authors explicitly caution that later hypocalcemia could have been missed and that the small subgroup receiving preoperative calcitriol could not establish its preventive utility. [3]

Before scheduling treatment, identify who will measure ionized calcium, interpret the trend and manage symptomatic deterioration. Reconcile observation capacity, laboratory access and transfer arrangements. Document an individualized supplementation and monitoring plan with the treating service rather than importing a fixed regimen from a retrospective cohort.

Keep early success and delayed complications separate

Guttin and colleagues' retrospective series involved 24 dogs undergoing 27 ethanol-ablation procedures. Some required another treatment after initial failure or development of another nodule. Hypocalcemia was documented after treatment, including delayed observations, and one dog developed signs requiring calcium supplementation. [4]

This procedure-based case series is useful for anticipating follow-up needs; it does not define a universally safe monitoring endpoint. Record resolution of hypercalcemia and absence of complications as separate outcomes. An initially satisfactory calcium value should not silently cancel the agreed follow-up.

Reassess associated urinary disease separately

The review describes urolithiasis among associated clinical problems. [1] Use the canine urolith dissolution and prevention pathway to address the stone's location, mineral composition and obstruction risk. Treating a parathyroid disorder does not answer those independent urinary decisions.

At discharge or transfer, carry forward the confirmed endocrine findings, procedure, histopathology if obtained, calcium trajectory, current medications and unresolved urinary or renal problems. Specify which service owns each recheck and which findings require urgent contact. Keep the continuing plan intelligible when care passes back to the referring practice.

Frequently Asked Questions

Does reference-interval PTH exclude primary hyperparathyroidism?

No. A nonsuppressed PTH can be inappropriate during ionized hypercalcemia. [1]

Does a neck nodule alone establish the endocrine diagnosis?

No. Establish the biochemical diagnosis and investigate alternatives before using cervical imaging for localization. [1]

Is ethanol ablation proven equivalent to surgery by the prospective study?

No. The single-center observational study did not randomize dogs between ablation and surgery. [2]

Does successful ablation mean complications cannot occur?

No. The prospective study reported both minor and major complications. [2]

Can the postoperative PTH study define a universal discharge cutoff?

No. Its retrospective, incomplete records, assay variation and early observation window limit that use. [3]

Does a normal early calcium result exclude later hypocalcemia?

No. The ethanol case series documented delayed hypocalcemia, including after the immediate postprocedure period. [4]

Did the PTH study establish whether prophylactic calcitriol prevents hypocalcemia?

No. Too few dogs received the studied preoperative exposure to support that conclusion. [3]